BACKGROUND: ATPase-family, AAA domain containing 3A (ATAD3A) is located on human chromosome 1p36.33, and high endogenous expression may associate with radio- and chemosensitivity. This study was conducted to investigate the significance of ATAD3A in glioblastoma multiforme (GBM). METHODS: Clinical significance of ATAD3A expression was assessed by immunohistochemistry in 67 GBM specimens, and prognostic value was assessed in 32 GBM patients statistically. To investigate in vitro phenotypic effects of ATAD3A, cell viability was measured using a clonogenic survival assay under either knockdown or ectopic expression of ATAD3A in GBM cell lines. The effects of ATAD3A knockdown on targeted DNA repair-associated proteins in T98G cells were evaluated using immunofluorescence and Western blotting. RESULTS: Clinically, high expression of ATAD3A was independent of O(6)-DNA methylguanine-methyltransferase methylation status and correlated with worse prognosis. In vitro, high ATAD3A-expressing T98G cells were more resistant to radiation-induced cell death compared with control and low endogenous ATAD3A U87MG cells. After silencing ATAD3A, T98G cells became more sensitive to radiation. On the other hand, enforced ATAD3A expression in U87MG cells exhibited increased radioresistance. ATAD3A may coordinate with aldo-keto reductase genes and participate in bioactivation or detoxication of temozolomide. Surprisingly, deficient DNA repair after irradiation was observed in T98G/ATAD3A knockdown as a result of decreased nuclear ataxia telangiectasia mutated kinase and histones H2AX and H3, which was also evidenced by the sustained elevation of poly (ADP-ribose) polymerase prior to and after radiation treatment. CONCLUSION: Our data suggest that high expression of ATAD3A is an independent biomarker for radioresistance in GBM. ATAD3A could be a potential target for therapy.
BACKGROUND:ATPase-family, AAA domain containing 3A (ATAD3A) is located on human chromosome 1p36.33, and high endogenous expression may associate with radio- and chemosensitivity. This study was conducted to investigate the significance of ATAD3A in glioblastoma multiforme (GBM). METHODS: Clinical significance of ATAD3A expression was assessed by immunohistochemistry in 67 GBM specimens, and prognostic value was assessed in 32 GBM patients statistically. To investigate in vitro phenotypic effects of ATAD3A, cell viability was measured using a clonogenic survival assay under either knockdown or ectopic expression of ATAD3A in GBM cell lines. The effects of ATAD3A knockdown on targeted DNA repair-associated proteins in T98G cells were evaluated using immunofluorescence and Western blotting. RESULTS: Clinically, high expression of ATAD3A was independent of O(6)-DNA methylguanine-methyltransferase methylation status and correlated with worse prognosis. In vitro, high ATAD3A-expressing T98G cells were more resistant to radiation-induced cell death compared with control and low endogenous ATAD3A U87MG cells. After silencing ATAD3A, T98G cells became more sensitive to radiation. On the other hand, enforced ATAD3A expression in U87MG cells exhibited increased radioresistance. ATAD3A may coordinate with aldo-keto reductase genes and participate in bioactivation or detoxication of temozolomide. Surprisingly, deficient DNA repair after irradiation was observed in T98G/ATAD3A knockdown as a result of decreased nuclear ataxia telangiectasia mutated kinase and histones H2AX and H3, which was also evidenced by the sustained elevation of poly (ADP-ribose) polymerase prior to and after radiation treatment. CONCLUSION: Our data suggest that high expression of ATAD3A is an independent biomarker for radioresistance in GBM. ATAD3A could be a potential target for therapy.
Entities:
Keywords:
ATAD3A; DNA repair; autophagy; glioblastoma multiforme; radiation
Authors: E Kirches; G Krause; M Warich-Kirches; S Weis; T Schneider; B Meyer-Puttlitz; C Mawrin; K Dietzmann Journal: Int J Cancer Date: 2001-08-15 Impact factor: 7.396
Authors: J S Smith; B Alderete; Y Minn; T J Borell; A Perry; G Mohapatra; S M Hosek; D Kimmel; J O'Fallon; A Yates; B G Feuerstein; P C Burger; B W Scheithauer; R B Jenkins Journal: Oncogene Date: 1999-07-15 Impact factor: 9.867
Authors: D Watters; P Kedar; K Spring; J Bjorkman; P Chen; M Gatei; G Birrell; B Garrone; P Srinivasa; D I Crane; M F Lavin Journal: J Biol Chem Date: 1999-11-26 Impact factor: 5.157
Authors: O Gires; M Münz; M Schaffrik; C Kieu; J Rauch; M Ahlemann; D Eberle; B Mack; B Wollenberg; S Lang; T Hofmann; W Hammerschmidt; R Zeidler Journal: Cell Mol Life Sci Date: 2004-05 Impact factor: 9.261
Authors: Tamar Harel; Wan Hee Yoon; Caterina Garone; Shen Gu; Zeynep Coban-Akdemir; Mohammad K Eldomery; Jennifer E Posey; Shalini N Jhangiani; Jill A Rosenfeld; Megan T Cho; Stephanie Fox; Marjorie Withers; Stephanie M Brooks; Theodore Chiang; Lita Duraine; Serkan Erdin; Bo Yuan; Yunru Shao; Elie Moussallem; Costanza Lamperti; Maria A Donati; Joshua D Smith; Heather M McLaughlin; Christine M Eng; Magdalena Walkiewicz; Fan Xia; Tommaso Pippucci; Pamela Magini; Marco Seri; Massimo Zeviani; Michio Hirano; Jill V Hunter; Myriam Srour; Stefano Zanigni; Richard Alan Lewis; Donna M Muzny; Timothy E Lotze; Eric Boerwinkle; Richard A Gibbs; Scott E Hickey; Brett H Graham; Yaping Yang; Daniela Buhas; Donna M Martin; Lorraine Potocki; Claudio Graziano; Hugo J Bellen; James R Lupski Journal: Am J Hum Genet Date: 2016-09-15 Impact factor: 11.025
Authors: Alexandra McAleenan; Claire Kelly; Francesca Spiga; Ashleigh Kernohan; Hung-Yuan Cheng; Sarah Dawson; Lena Schmidt; Tomos Robinson; Sebastian Brandner; Claire L Faulkner; Christopher Wragg; Sarah Jefferies; Amy Howell; Luke Vale; Julian P T Higgins; Kathreena M Kurian Journal: Cochrane Database Syst Rev Date: 2021-03-12
Authors: Le Tang; Fang Wei; Yingfen Wu; Yi He; Lei Shi; Fang Xiong; Zhaojian Gong; Can Guo; Xiayu Li; Hao Deng; Ke Cao; Ming Zhou; Bo Xiang; Xiaoling Li; Yong Li; Guiyuan Li; Wei Xiong; Zhaoyang Zeng Journal: J Exp Clin Cancer Res Date: 2018-04-23